Cognition Therapeutics (NASDAQ:CGTX) Stock Rating Upgraded by Wall Street Zen

Cognition Therapeutics (NASDAQ:CGTX) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Friday.

CGTX has been the subject of a number of other research reports. Chardan Capital restated a “buy” rating and set a $4.00 price target on shares of Cognition Therapeutics in a report on Friday, August 8th. HC Wainwright restated a “buy” rating and set a $3.00 price target on shares of Cognition Therapeutics in a report on Thursday, June 26th. One investment analyst has rated the stock with a Strong Buy rating and three have assigned a Buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $2.83.

Cognition Therapeutics Stock Up 0.8%

NASDAQ:CGTX opened at $2.61 on Friday. Cognition Therapeutics has a 52 week low of $0.22 and a 52 week high of $3.83. The stock has a market capitalization of $191.89 million, a PE ratio of -3.90 and a beta of 1.33. The stock’s 50-day moving average price is $1.23 and its 200-day moving average price is $0.67.

Cognition Therapeutics (NASDAQ:CGTX) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.01. Sell-side analysts expect that Cognition Therapeutics will post -0.8 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cognition Therapeutics

Several institutional investors have recently modified their holdings of CGTX. Acadian Asset Management LLC grew its position in Cognition Therapeutics by 814.1% during the first quarter. Acadian Asset Management LLC now owns 1,007,586 shares of the company’s stock worth $422,000 after buying an additional 897,353 shares during the period. CM Management LLC grew its position in Cognition Therapeutics by 100.0% during the first quarter. CM Management LLC now owns 400,000 shares of the company’s stock worth $168,000 after buying an additional 200,000 shares during the period. Two Sigma Investments LP grew its position in Cognition Therapeutics by 372.2% during the fourth quarter. Two Sigma Investments LP now owns 53,691 shares of the company’s stock worth $38,000 after buying an additional 42,321 shares during the period. Finally, Northeast Financial Consultants Inc grew its position in Cognition Therapeutics by 158.6% during the first quarter. Northeast Financial Consultants Inc now owns 63,351 shares of the company’s stock worth $27,000 after buying an additional 38,851 shares during the period. 43.35% of the stock is owned by hedge funds and other institutional investors.

About Cognition Therapeutics

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.